Business Context and Reporting Period
This Form 8-K, filed on August 3, 2026, by Indivior Pharmaceuticals, Inc. (Indivior), announces the execution of an Agreement and Plan of Merger dated August 1, 2026. The agreement is between Indivior, Supernus Pharmaceuticals, Inc. (Supernus), and Artemis Merger Sub Inc., a wholly-owned subsidiary of Indivior. The transaction is structured as a "merger of equals."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for either company. The document references non-GAAP financial measures such as Adjusted EBITDA and cost synergies in the context of the transaction but does not disclose the numerical figures within this report.
Material Changes
The primary material change is the formal agreement to merge Indivior and Supernus. The filing notes that the combined company will incur additional indebtedness to fund a Special Dividend, though the specific amount is not disclosed in this text. No other operational or financial changes for the reporting period are detailed.
Guidance, Outlook, and Risks
Management expects the transaction to generate benefits, synergies, and cost savings, though no specific guidance figures are provided. The filing outlines significant risks that could prevent the merger from closing or alter its terms, including:
- Failure to obtain required stockholder or regulatory approvals.
- Business disruption and diversion of management attention.
- Failure to realize anticipated synergies or cost savings.
- Impact of additional indebtedness incurred for the Special Dividend.
- Macroeconomic conditions, including economic downturns and trade disputes.
- Stockholder litigation or competing acquisition proposals.
Investors are directed to a forthcoming joint proxy statement/prospectus (Form S-4) for detailed financial information and voting materials.
Investor Verification Checklist
- Verify the definitive terms of the merger, including the exchange ratio and Special Dividend amount, in the upcoming joint proxy statement/prospectus.
- Confirm the status of regulatory approvals required for the transaction to close.
- Review the specific financial projections and synergy estimates in the Investor Presentation (Exhibit 99.1) referenced in the filing.
- Assess the impact of the additional indebtedness on the combined company's liquidity and leverage ratios.
- Monitor for any competing acquisition proposals or termination fee triggers.